Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 3
1999 8
2000 8
2001 15
2002 12
2003 20
2004 27
2005 20
2006 13
2007 16
2008 12
2009 10
2010 15
2011 16
2012 12
2013 6
2014 6
2015 5
2016 5
2017 4
2018 2
2019 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

216 results
Results by year
Filters applied: . Clear all
Page 1
RNA-Targeted Therapeutics
Crooke ST, et al. Cell Metab 2018 - Review. PMID 29617640 Free article.
Antisense antimicrobial therapeutics.
Sully EK and Geller BL. Curr Opin Microbiol 2016 - Review. PMID 27375107 Free PMC article.
The sequence-specificity and short length of antisense antimicrobials also pose little risk to human gene expression. Because antisense antimicrobials are a platform technology, they can be rapidly designed and synthesized to target almost any microbe. ...Recent work has shown that antisense technology has the potential to address the antibiotic-resistance crisis, since resistance mechanisms for standard antibiotics apparently have no effect on antisense antimicrobials. ...
The sequence-specificity and short length of antisense antimicrobials also pose little risk to human gene expression. Because anti
G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons
Volpicelli-Daley LA, et al. J Neurosci 2016. PMID 27413152 Free PMC article.
Knockdown of total α-synuclein with potent antisense oligonucleotides substantially reduces inclusion formation in G2019S-LRRK2-expressing neurons, suggesting that LRRK2 influences α-synuclein inclusion formation by altering α-synuclein levels. ...
Knockdown of total α-synuclein with potent antisense oligonucleotides substantially reduces inclusion formation in G2019S-LRRK2-expre …
Different cancers, same target?
Villegas J, et al. Aging (Albany NY) 2017. PMID 28800297 Free PMC article.
Nano-graphene oxide improved the antibacterial property of antisense yycG RNA on Staphylococcus aureus.
Wu S, et al. J Orthop Surg Res 2019. PMID 31492154 Free PMC article.
CONCLUSIONS: Our findings demonstrated that nano-GO with antisense yycG RNA is a more effective and relatively stable strategy for the management of S. aureus infections....
CONCLUSIONS: Our findings demonstrated that nano-GO with antisense yycG RNA is a more effective and relatively stable strategy for th …
Targeting the Dvl-1/β-arrestin2/JNK3 interaction disrupts Wnt5a-JNK3 signaling and protects hippocampal CA1 neurons during cerebral ischemia reperfusion
Wei X, et al. Neuropharmacology 2018. PMID 29510185
AS-β-arrestin2 (an antisense oligonucleotide against β-arrestin2) and RRSLHL (a small peptide that competes with β-arrestin2 for binding to JNK3) were applied to confirm the positive signal transduction effect of the Dvl-1-β-arrestin2-JNK3 signaling module during cerebral I/R. ...
AS-β-arrestin2 (an antisense oligonucleotide against β-arrestin2) and RRSLHL (a small peptide that competes with β-arrestin2 for bind …
Folate-targeted therapies for cancer
Xia W and Low PS. J Med Chem 2010 - Review. PMID 20666486
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis
Yamaguchi K, et al. Hepatology 2007. PMID 17476695
DGAT2 antisense oligonucleotide (ASO) treatment improved hepatic steatosis dramatically in a previous study of obese mice. According to the 2-hit hypothesis for progression of NAFLD, hepatic steatosis is a risk factor for nonalcoholic steatohepatitis (NASH) and fibrosis. ...
DGAT2 antisense oligonucleotide (ASO) treatment improved hepatic steatosis dramatically in a previous study of obese mice. According …
216 results
Jump to page
Feedback